These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29617934)

  • 21. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.
    Lim J; Lomax AJ; McNeil C; Harrisberg B
    Ocul Immunol Inflamm; 2018; 26(4):628-631. PubMed ID: 27892777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
    Zaloum A; Falet JR; Elkrief A; Chalk C
    Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
    [No Abstract]   [Full Text] [Related]  

  • 23. Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma.
    Mistry HB; Orrell D; Eftimie R
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):325-332. PubMed ID: 29222604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple Therapy Improves Colorectal Cancer Response.
    Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
    Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
    Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Laske J; Meier F; Bauer A; Beissert S; Garzarolli M
    Melanoma Res; 2018 Oct; 28(5):485-487. PubMed ID: 30148769
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful use of crushed formulation of dabrafenib and trametinib in a pediatric glioneural tumor.
    Mamdouhi T; Vagrecha A; Johnson AA; Levy CF; Atlas M; Krystal JI
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29187. PubMed ID: 34185373
    [No Abstract]   [Full Text] [Related]  

  • 28. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
    Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
    [No Abstract]   [Full Text] [Related]  

  • 29. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
    Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GSK drug combination approved for advanced melanoma.
    Inman S
    Am J Manag Care; 2014 Feb; 20(2 Spec No.):E10. PubMed ID: 25764581
    [No Abstract]   [Full Text] [Related]  

  • 31. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
    Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
    Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
    [No Abstract]   [Full Text] [Related]  

  • 32. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
    Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
    Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dabrafenib Active in Rare NSCLC Subtype.
    Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barre Syndrome due to Adjuvant Therapy with Dabrafenib Plus Trametinib.
    Geçgel A; Ön S; Çiftçi Y; Özkan O; Açar FP; Karaca B
    Balkan Med J; 2024 Jul; 41(4):312-313. PubMed ID: 38572561
    [No Abstract]   [Full Text] [Related]  

  • 35. [A woman with a skin lesion suspected for melanoma].
    Post NF; Huis In 't Veld E; Crijns MB
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib.
    Shimada S; Fukushima S; Niimori D; Miyashita A; Setoyama H; Sasaki Y; Ihn H
    J Dermatol; 2018 Jun; 45(6):e157-e158. PubMed ID: 29315749
    [No Abstract]   [Full Text] [Related]  

  • 37. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
    Long GV; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Grob JJ; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JB; Hansson J; Utikal J; Ferraresi V; Kovalenko N; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; DeMarini DJ; Irani JG; Swann S; Legos JJ; Jin F; Mookerjee B; Flaherty K
    Lancet; 2015 Aug; 386(9992):444-51. PubMed ID: 26037941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.